Single Effects of Apolipoprotein B, (a), and E Polymorphisms and Interaction between Plasminogen Activator Inhibitor-1 and Apolipoprotein(a) Genotypes and the Risk of Coronary Artery Disease in Czech Male Caucasians

Beneš, Petr; Mužı́k, Jan; Benedı́k, Jaroslav; Frélich, Milan; Elbl, Lubomı́r; Vašků, Anna; Znojil, Vladimı́r; Vácha, Jiří

doi:10.1006/mgme.1999.2957

Cited by 20 publications

(12 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Frequencies of ApoE genotypes in our group of CAD patients were, in general, consistent with other studies referring to ApoE and CAD performed in Central European populations including Czech 28,39,52 . The strengths and limitations of our control group are discussed further.…”

supporting

confidence: 92%

“…The results of those studies are controversial however. Some found no correlation between the severity of CAD and ApoE polymorphism 38,39 , while others established deleterious effect of ApoE4 isoform and protective effect of E2 isoform on the number of affected coronary vessels 36,37 in various populations. The severity of stenoses has been found to follow the same manner in male Chinese 37 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Apolipoprotein E polymorphism is associated with both number of diseased vessels and extent of coronary artery disease in Czech patients with CAD

Máchal¹,

Vašků²,

Hlinomaz³

et al. 2012

BIOMED PAP

View full text Add to dashboard Cite

Aims. The impact of ApoE polymorphism on angiographic parameters was assessed in patients referred for coronary angiography. Methods. Elective coronary angiography was performed in 671 subjects (525 men, 146 women, mean age 60±10 years) with symptoms of ischemic heart disease. The patients were divided into: no CAD group (smooth coronary vessels, n=83), one-vessel (n=155), two-vessel (n=170) and three-vessel disease (n=196). Patients with stenoses 0-50% were excluded. Within patients with CAD, we evaluated overall extent of CAD measured by the number of stenotic segments according to AHA (1 segment vs. 2-3 vs. ≥4), and the severity of the most serious stenosis (in percent). ApoE genotype was determined using real-time PCR. Results. The frequency of ε2/ε3 genotype (n=56) was lower in the three-vessel disease group compared to one-vessel disease (OR=0.25, P=0.0019), two-vessel disease (OR=0.31, P=0.0114) or no CAD group (OR=0.24, P=0.0057). Frequency of ε2/ε3 decreased with the number of affected segments (1 vs. ≥4: OR=0.35, P=0.0143). The ε3/ε4+ε4/ε4 genotypes (n=123) were more frequent in CAD patients altogether compared with no CAD group (OR=2.30, P=0.019), while no impact of the ε4 allele on angiographic parameters within the CAD patients was detected. In ε2/ε3 carriers with CAD, lower LDL-cholesterol, total cholesterol and lower use of lipid-lowering drugs were observed. Conclusions. The results show predominantly focal form of CAD in patients with ε2/ε3 genotype. Lower LDL-cholesterol and total cholesterol may play the key role, although other contributing factors are discussed.

show abstract

supporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Apolipoprotein E polymorphism is associated with both number of diseased vessels and extent of coronary artery disease in Czech patients with CAD

Máchal¹,

Vašků²,

Hlinomaz³

et al. 2012

BIOMED PAP

View full text Add to dashboard Cite

show abstract

“…The remaining 40 publications reported potentially relevant data. Eleven of these provided a complete report of all data that were determined in the study (Benes et al 2000b;Aalto-Setala et al 1998;Bohn et al 1994;Gardemann et al 1998;Louhija et al 1994;Miettinen et al 1994;Pajukanta et al 1996;Salazar et al 2000;Vilella et al 1992;Visvikis et al 1993;Wick et al 1995). For the remaining 29 publications, the principal investigator was requested to provide data that were not shown in the article, and for 13 of these publications, additional data were provided (Abbey et al 1995;Benes et al 2000a;Bohn et al 1993;Corbo et al 1997;Delghandi et al 1999;Hixson et al 1992;Iso et al 1996;Lopez-Miranda et al 1997Marshall et al 1994;Moreel et al 1992;Turner et al 1995;Ukkola et al 1993).…”

Section: Literature Searchmentioning

confidence: 97%

Molecular variation at the apolipoprotein�B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis

et al. 2003

View full text Add to dashboard Cite

Apolipoprotein B (apoB) is the sole protein component of low-density lipoprotein (LDL) and is thought to play an important role in atherogenesis. We performed a meta-analysis of the associations between the three most frequently investigated polymorphisms (XbaI, signal peptide insertion/deletion, EcoRI) in the apolipoprotein B (APOB) gene, lipid parameters, and the risk of ischemic heart disease (IHD). We restricted our analysis to Caucasians. Homozygotes for the XbaI X+ allele had significantly elevated levels of LDL cholesterol (LDL-C) and apoB, but a decreased risk (OR=0.80; 95%CI: 0.66-0.96) of IHD. Homozygosity for the signal peptide deletion allele was associated with similarly increased levels of LDL-C and apoB, and with an increased risk of IHD (OR=1.30; 95%CI: 1.08-1.58). Subjects homozygous for the rare EcoRI allele had significantly decreased levels of total and LDL cholesterol, but unaltered risk of IHD. We conclude that all three polymorphic apoB sites are associated with altered lipid levels, but not necessarily with a consistently altered risk of IHD. These data suggest that the relationship between apoB levels, hypercholesterolemia and IHD risk cannot have a simple molecular basis in the apoB gene.

show abstract

“…The data linking polymorphisms in the 5)-flanking region of the apo(a) gene to the increased risk of coronary atherosclerosis are controversial. Shorter repeats of the (TTTTA) n polymorphism have been associated with CAD and high plasma Lp(a) concentrations in Czech and Japanese populations [37,40,78]. Chimienti et al [79] also found a decreased frequency of apo(a) alleles with 9 TTTTA repeats in Italian subjects with a history of MI and an inverse association of the (TTTTA) n polymorphism with plasma Lp(a) in controls.…”

Section: Other Apo(a) Polymorphisms and The Risk Of Cadmentioning

confidence: 83%

“…No direct effect of this polymorphism on the rate of apo(a) transcription has been observed in vitro [43,44]. On the other hand, positive but contradictory associations with CAD have been reported in different populations [37,40,[78][79][80][81]. Large and complex association and family studies in different populations, together with in vitro expression and functional studies, should clarify the future importance of the so-far-identified positive apo(a) variant-plasma Lp(a) associations.…”

Section: Existence Of Multiple Linkage Disequilibriamentioning

confidence: 99%

Polymorphisms in the Apolipoprotein(a) Gene, Plasma Lp(a) and Cardiovascular Risk

Beneš¹

2003

Heart Drug

Self Cite

View full text Add to dashboard Cite

Increased plasma concentration of lipoprotein(a) [Lp(a)] represents an established risk factor for coronary artery disease (CAD). The plasma Lp(a) level is relatively stable during life and it is more than 90% genetically determined by the apolipoprotein(a) [apo(a)] gene. Numerous polymorphisms have been identified in the apo(a) gene. The extreme apo(a) protein size polymorphism, based on the variable number of so-called kringle IV type 2 repeats (KIV-2), accounts for a large portion of variability of plasma Lp(a) levels. Moreover, it has been shown that several other apo(a) sequence changes, both in the coding and regulatory sequences, influence plasma Lp(a) levels and/or Lp(a) prothrombogenic properties. Associations between some of them and the increased risk of CAD have also been reported. However, the existence of strong linkage disequilibria in the apo(a) locus represents a serious problem to identify a real effect of single polymorphism on Lp(a) phenotype. Large and complex association and family studies in different populations, together with in vitro expression and functional studies, should clarify the importance of so far identified positive apo(a) polymorphism-plasma Lp(a) associations in the future. In addition, standardization of measurement of Lp(a) is necessary to allow comparison of results obtained with different immunoassays.

show abstract

Single Effects of Apolipoprotein B, (a), and E Polymorphisms and Interaction between Plasminogen Activator Inhibitor-1 and Apolipoprotein(a) Genotypes and the Risk of Coronary Artery Disease in Czech Male Caucasians

Cited by 20 publications

References 46 publications

Apolipoprotein E polymorphism is associated with both number of diseased vessels and extent of coronary artery disease in Czech patients with CAD

Apolipoprotein E polymorphism is associated with both number of diseased vessels and extent of coronary artery disease in Czech patients with CAD

Molecular variation at the apolipoprotein�B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis

Polymorphisms in the Apolipoprotein(a) Gene, Plasma Lp(a) and Cardiovascular Risk

Contact Info

Product

Resources

About